Skip to content

Chemical Screening Optimization X01 Eligibility Guide

Updated 5 official sources

Quick Answer: Chemical Screening and Optimization Facility X01 eligibility starts with 6 steps: confirm reproductive-health fit, pick the NICHD service, show development stage, set a 12-month service plan, name output-evaluation capacity, and check whether a current reissue exists.

Full answer and how we checked it

NIH PAR-23-193 supported service requests for non-hormonal contraceptive and reproductive-health product development. Selected applicants receive resource access, not a Notice of Award.

Who this is for: Investigators, translational research teams, reproductive-health researchers, university technology groups, and sponsored-research offices deciding whether a contraceptive or reproductive-health product needs NICHD facility services rather than an R01, SBIR/STTR, R21, contract, or private development path.

Data note: This guide uses NIH PAR-23-193, NICHD context, Grants.gov listing data, NIH X01 activity-code context, the live Grantsights program record, and Grantsights award-data signals checked on June 3, 2026.

In this guide

Quick Facts

Agency
HHS
Last deadline
Apr 3, 2026 (passed)
Status
Closed

Assistance Listing 93.865: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.865, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
5,330
Avg Award (whole listing)
$2,808,443
Median Award (whole listing)
$1,224,444
Total Funding (FY2024, whole listing)
$1.2B
YoY Funding Trend
+1%

Data last verified: May 18, 2026

Chemical Screening and Optimization Facility X01 is easy to misunderstand because it looks like a funding opportunity but behaves like a resource-access path. According to NIH PAR-23-193, the X01 does not result in a Notice of Award. Successful applicants receive instructions for accessing the facility resources described in the NOFO.

According to NICHD (opens in a new tab), reproductive health research includes contraception, fertility, pregnancy, and related development needs. That mission boundary matters because a general screening request can be technically strong and still be wrong for this facility-access route.

Use this guide with the live Chemical Screening and Optimization Facility X01 program record, then compare NIH grants complete guide, SBIR grants complete guide, NIH R01, R21, R03, and K award comparison, what is a NOFO, and the Grantsights grant database.

Source check, June 3, 2026: What official NIH and Grants.gov pages don't tell you is whether the user needs facility access or cash. Grantsights analysis compares X01 resource-access rules, reproductive-health mission fit, service readiness, active-award overlap, and alternate NIH or SBIR routes. NIH's source record still marks PAR-23-193 expired after the April 3, 2026 receipt date, so the next action is to check for a reissue before drafting and apply only if the requested facility service can move a candidate, method, or device toward a defined milestone within the service window.

For example, a hypothetical non-hormonal contraceptive team with a testable lead, a clear DMPK need, and a named evaluation owner could be a strong X01 fit. A reproductive biology lab that mainly needs salary, animal work, or open-ended discovery should skip X01 and compare R01, R21, SBIR/STTR, or private development support. The bad fit is treating resource access like a small cash grant.

Chemical Screening and Optimization Facility X01 Eligibility: 5 Stop Checks

5 stop checks decide whether the X01 is worth drafting before the team spends 30 days on a request. First, the project should fit contraceptive or reproductive-health related product development. Second, the team should need facility services, not direct research funds. Third, the requested service should help move a compound, method, or device toward clinical evaluation. Fourth, the applicant should be able to evaluate produced materials quickly. Fifth, the team should check whether a current reissue exists because NIH still displayed PAR-23-193 as expired during the June 3 source check.

Stop checkStrong X01 signalRed flag
Product areaContraceptive or reproductive-health product pathGeneral drug discovery outside scope
Request typeFacility service accessCash support or salary need
StagePreclinical development needing screening or optimizationBasic discovery with no development path
TimelineService plan within 12 monthsUndefined work plan
OutputData or materials that applicant can evaluateNo internal evaluation capacity

Teams sometimes confuse X01 with a small grant. That mistake matters. If the real need is personnel, animal studies, or lab operating support, the X01 may not solve the problem.

What NIH Doesn't Tell You

4 weeks of planning should answer 4 practical questions between the official NOFO and a good decision, and Grantsights' take is direct: skip this if you need cash more than facility access. First, NIH does not decide whether the project is ready for a facility service. The applicant has to show that the requested service will move the compound, method, or device toward clinical evaluation.

Second, NIH does not give the applicant cash. The X01 gives access to resources, which means the team still needs internal capacity to use outputs. If the facility generates materials and the applicant can't evaluate them, the service path breaks.

Third, NIH does not make the reproductive-health fit broad. A general small-molecule screening need may be real, but this route is tied to NICHD's contraceptive and reproductive-health product-development goals.

Fourth, NIH does not choose between X01 and a funded mechanism. If the project needs salaries, supplies, animal work, or broad research aims, the team should compare R01, R21, SBIR/STTR, or private development support before using X01.

6 Services The Facility Can Support

6 service categories should be visible in the first scan, and each should tie to a 12-month service plan with 1 owner within 30 days. NIH lists potential support including protein generation, protein crystallization optimization, protein co-crystallization with ligand, crystallization analysis, high-throughput screening, computational chemistry, chemical optimization, ADME studies, DMPK studies, and formulation optimization.

Service areaBest-fit use
High-throughput screeningFind or evaluate candidate activity
Chemical optimizationImprove properties of a hit or lead
Protein generationSupport target work or assay setup
CrystallographyUnderstand binding and structure
ADME and DMPKAssess early development properties
Formulation supportMove a candidate toward a usable product form

According to NIH, the long-term objective is to help reach a preclinical candidate for IND or IDE studies. A basic biology question with no candidate path may be important, but it is not the cleanest fit here.

4 No-Award Rules That Change The Strategy

4 no-award rules change how applicants should think in the first 2 pages and first 30 days. First, an X01 does not produce a Notice of Award. Second, selected applicants receive access to facility resources. Third, service requests do not receive standard peer review. Fourth, NIH staff evaluate requests using the criteria in the NOFO.

That is a major conversion point. Users searching "X01 eligibility" may assume they are applying for a grant. It should also explain that selected applicants will work through NIH communications with the facility during the project.

The best applicant is not the team with the most expensive plan. It is the team with a clear service need, a strong development path, and the ability to use outputs quickly.

5 Review Criteria Applicants Should Answer

5 review criteria should shape the request, especially for services lasting 6 months to 1 year. NIH PAR-23-193 asks whether the requested service is likely to lead to significant movement of the compound, method, or device toward clinical evaluation. NIH also asks whether the strategy includes success markers, timeline, and milestones for service requests lasting 6 months to 1 year.

For screening and service requests, NIH asks whether the applicant has addressed items such as protein production, novel chemical entities, and off-target effects from broad agonism or antagonism. NIH also asks whether the applicant has adequate resources to evaluate materials produced by the facility in a timely way, with the NOFO giving a 2-week example.

The applicant should be able to answer: what service, why now, what milestone, what success marker, what risk, and who evaluates the output.

According to USAspending.gov (opens in a new tab) data, assistance listing 93.865 had about $1.24B in FY2024 obligations across about 5,360 awards active that year. That family-level context shows NIH scale, but it does not change the X01 fact pattern: this specific route is access to facility services, not a standard cash award.

5 Bad-Fit Signals To Stop Early

5 bad-fit signals should stop the sprint before a 30-day request cycle starts and before 6 months of service planning begins. First, the project does not connect to contraception or reproductive health. Second, the team needs cash funding rather than facility services. Third, the project is still too early, with no target, assay, compound, method, or device path. Fourth, the applicant cannot evaluate facility outputs quickly. Fifth, the requested services overlap with work already funded through Public Health Service support.

NIH PAR-23-193 says requested services may not overlap with efforts already funded through the Public Health Service. That matters for teams with active NIH awards. The X01 should not be used to double-cover work already paid for.

Don't try to fix a bad fit with broader language. A non-reproductive oncology screening project, a general medicinal chemistry need, or a salary-support request should move to another route.

5 Adjacent Routes To Compare

5 adjacent routes can be cleaner, and teams should compare them before drafting for 30 days. R01 may fit hypothesis-driven reproductive biology or product-development research with a full research plan. R21 may fit early exploratory work. SBIR/STTR may fit a small business developing a product. Contracts or translational-development programs may fit service procurement. Foundation or private capital may fit product-development work outside NIH scope.

RouteBetter first read when...Why
X01 CSOFNeed NICHD facility servicesResource access is the point
R01Need full research fundingCash award and research aims fit
R21Need exploratory pilot workEarlier stage than service access
SBIR/STTRSmall business product pathCommercial development route
Private or contract pathNeed vendor work outside NIH scopeFaster or more flexible

For broader NIH route choice, use NIH grants complete guide. If the applicant is a small business, compare SBIR grants complete guide before using the X01 path.

If the team is choosing among research mechanisms, compare NIH R01, R21, R03, and K awards. If the team is still parsing the opportunity document, start with what is a NOFO.

30-Day CSOF Readiness Plan

30 days is enough to test whether the X01 fits. Week 1 should define the product-development question. Is the team trying to advance a contraceptive or reproductive-health compound, method, or device? Week 2 should choose the service request. Screening, protein work, crystallography, ADME, DMPK, and formulation support require different readiness evidence.

Week 3 should write success markers, timeline, and milestones. If services run 6 months to 1 year, NIH expects milestone thinking. Week 4 should contact the scientific contact and confirm whether a current reissue exists. PAR-23-193 expired on April 4, 2026, so current-cycle checking matters.

One investigator with a non-hormonal contraceptive lead that needs DMPK and formulation support may fit. One investigator with a general reproductive biology hypothesis and no service-ready product path may need R01 or R21 first.

6 Real-World CSOF X01 Scenarios

6 scenarios show the difference between good and weak fit over a 12-month service plan. One university in Pennsylvania with a non-hormonal contraceptive lead and a clear DMPK question may fit. One company in California needing high-throughput screening for a reproductive-health target may fit if it can evaluate outputs quickly.

One university in Michigan with a broad fertility-biology hypothesis but no candidate path should likely use R01 or R21 first. One company in California with a general oncology screening need should not force the project into this NICHD route. One investigator with an active NIH award already paying for the same services should check overlap before moving. One team needing salary and animal-study funds should compare SBIR/STTR or R01 rather than X01.

An X01 request is not ready until the applicant can name the requested service, target or candidate, milestone, success marker, timeline, and evaluation owner.

Sources

Largest awards active in FY2024

One row per recipient, its largest award | 5,330 Assistance Listing records | Avg: $2.8M

REAL DATA
1

Fred Hutchinson Cancer Center

WA

$1.1B
2

Family Health International

NC

$700.6M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Next steps

Where to go next

These next pages help you move from research into a specific grant choice.

Frequently Asked Questions

What does the Chemical Screening and Optimization Facility X01 provide?

The NIH NOFO lets investigators request NICHD facility services such as high-throughput screening, chemical optimization, protein generation, crystallography, ADME, DMPK, and formulation support.

Does an X01 create a grant award?

No. NIH says this X01 does not result in a Notice of Award; selected applicants receive access to resources.

How long can services last?

NIH says services should not exceed 12 months in planned duration unless approved before application submission.

Who should skip this X01?

Skip it if the project does not involve contraceptive or reproductive-health product development, lacks a testable compound, method, or device path, or needs cash funding rather than facility access.

Is PAR-23-193 still active?

PAR-23-193 expired on April 4, 2026, so applicants should check NIH for a reissue before drafting.

Last updated October 10, 2026. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.